drugset / Trial / NCT07011485

A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.

NCT07011485

Phase 2 Active not recruiting 15 enrolled PDFE Pharma Innovations FZCO
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety and efficacy of PDFE-2304 compared with Minoxidil 5% in men with androgenic alopecia (AGA).

Timeline

Start
2025-05-14
Primary completion
2025-08-14
Completion
2025-09-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Minoxidil Small molecule 1 ml Topical
Comparator Minoxidil Small molecule 5 % Topical
Subject PDFE-2304 Unknown 1 ml Topical

Indications